Ovarian cancer presents significant challenges due to its tumor microenvironment—a complex network of cells, molecules, and ...

By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for ...

Emily Bond, then 37, noticed a slight difference in her nipple and visited her doctor. She later learned had Stage 2 breast ...

Tumours shrank or stopped growing in almost one in three women (31 per cent) with low-grade serous ovarian cancer, which does ...

A University of Iowa research team led by Jill Kolesar, UI College of Pharmacy dean and professor, has received an $8.8 ...

Scientists say the Royal Marsden hospitals' drug trial could change practice globally for serous form of ovarian cancer which ...

Experts are so excited by the latest findings that they hope the treatment will change practice globally for this type of ...

Results from the RAMP 201 clinical trial are promising for patients with recurrent low-grade serous ovarian cancer.

Professor Susana Banerjee, from the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research said the findings ...

In this enlightening conversation, ovarian cancer survivors come together to discuss the pivotal role support groups play in ...

Trish Kifer was treated by University of Colorado Cancer Center member Saketh Guntupalli, MD. Before her ovarian cancer ...